12 completed, 2 unknown, 2 withdrawn, 1 recruiting. 18 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 12, Unknown 2, Withdrawn 2, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Gambling: new trials by email Literature Review of Gambling trials Research Report on Gambling
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study Psychotherapy assisted by high-dose psilocybin (25mg or 40mg where appropriate), Psychotherapy assisted by low-dose psilocybin (1 mg) - Gambling Disorder | Phase 2 | Recruiting | Nantes University Hospital | 30 | 2026-10-08 | 2026-10-16 |
| RCT for Gambling and Naltrexone, Using Use Eye-tracking Analysis to Predict Treatment Response Naltrexone, Placebo - Eye Tracking, Gambling Disorder | Phase 2 | Unknown | University of Sao Paulo | 40 | 2021-06-01 | 2021-02-04 |
| Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder Naloxone hydrochloride, Placebo - Pathological Gambling, Gambling Disorder | Phase 2 | Unknown | Finnish Institute for Health and Welfare | 126 | 2018-02-22 | 2019-07-16 |
| Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray Naloxone hydrochloride 20mg/ml - Gambling, Opioid | Phase 2 | Completed | Finnish Institute for Health and Welfare | 20 | 2017-02-14 | 2019-09-12 |
| Milk Thistle in Pathological Gambling Placebo, Milk Thistle - Pathological Gambling, Gambling Disorder | Phase 2 | Completed | University of Chicago | 55 | 2015-01-01 | 2026-07-07 |
| Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling CRAFT treatment, Treatment as Usual - Pathological Gambling | Phase 2 | Withdrawn | Colchester East Hants Health Authority | 2011-06-03 | 2020-01-23 | |
| Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble Ecopipam - Pathological Gambling | Phase 2 | Completed | Emalex Biosciences Inc. | 34 | 2010-10-01 | 2024-05-14 |
| N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers N Acetyl Cysteine, Sugar Pill - Gambling, Tobacco Use Disorder | Phase 2 | Completed | University of Chicago | 28 | 2009-09-01 | 2023-03-21 |
| D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement Haloperidol, Fluphenazine, Dexedrine - Pathological Gambling | Phase 2 | Completed | Centre for Addiction and Mental Health | 60 | 2009-09-01 | 2016-04-25 |
| Tolcapone Treatment of Pathological Gambling Tolcapone - Pathological Gambling | Phase 2 | Completed | University of Chicago | 24 | 2009-06-01 | 2023-02-23 |
| Topiramate Trial for Pathological Gamblers Topiramate flexible dosage, Placebo matching tablets, 4-session gambling cognitive restructuring - Pathological Gambling | Phase 2 | Completed | University of Sao Paulo | 38 | 2009-06-01 | 2013-05-03 |
| Investigation of Naltrexone for Pathological Gambling Naltrexone, Placebo - Pathological Gambling | Phase 2 | Completed | Yale University | 9 | 2009-02-01 | 2017-10-13 |
| Memantine Treatment Study of Pathological Gambling Memantine Hydrochloride - Pathological Gambling | Phase 2 | Completed | Yale University | 29 | 2007-12-01 | 2013-04-08 |
| Topiramate on Gambling-Related Behaviours Topiramate - Gambling | Phase 2 | Withdrawn | Centre for Addiction and Mental Health | 2006-09-01 | 2015-07-22 | |
| Cognitive Behavioral Therapy for Pathological Gambling Cognitive Behavioral Therapy, Wait-list - Pathological Gambling | Phase 2 | Completed | University of Minnesota | 76 | 2006-06-01 | 2010-01-05 |
| Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling nalmefene HCl, Placebo - Pathological Gambling | Phase 2 / Phase 3 | Completed | Somaxon Pharmaceuticals | 233 | 2005-08-01 | 2008-05-19 |
| Indicated Prevention With At-Risk Gamblers Personalized Feedback Intervention, Cognitive Behavioral Intervention - Gambling, Pathological Gambling | Phase 2 | Completed | University of Washington | 225 | 2003-07-01 | 2013-12-11 |
| Effectiveness of Sertraline in Treating Pathological Gamblers With a Diagnosis of Alcohol Dependence - 1 Sertraline, Relapse Prevention Therapy - Alcoholism, Gambling | Phase 2 | Terminated | New York State Psychiatric Institute | 9 | 2001-12-01 | 2017-10-27 |
Alcoholism (1) · Behavior, Addictive (1) · Tobacco Use Disorder (1)
Behavior (18) · Disruptive, Impulse Control, and Conduct Disorders (18) · Mental Disorders (18) · Risk-Taking (18) · Chemically-Induced Disorders (2) · Substance-Related Disorders (2) · Alcohol-Related Disorders (1) · Compulsive Behavior (1) · Impulsive Behavior (1)
Cognitive Behavioral Therapy (2) · Naloxone (2) · Naltrexone (2) · Sugars (2) · Acetylcysteine (1) · Dextroamphetamine (1) · Fluphenazine (1) · Haloperidol (1) · Lactose (1) · Memantine (1) · Psilocybin (1) · Secondary Prevention (1) · Sertraline (1) · Silymarin (1) · Therapeutics (1)
University of Chicago (3) · Centre for Addiction and Mental Health (2) · Finnish Institute for Health and Welfare (2) · University of Sao Paulo (2) · Yale University (2) · Colchester East Hants Health Authority (1) · Emalex Biosciences Inc. (1) · Nantes University Hospital (1) · New York State Psychiatric Institute (1) · Somaxon Pharmaceuticals (1) · University of Minnesota (1) · University of Washington (1)
United States (8) · Canada (3) · Finland (2) · Brazil (1) · France (1)
Hannu Alho, Prof. (2) · Jon E Grant, MD, JD (2) · Jon E Grant, MD, JD, MPH (2) · Carlos Blanco, M.D. (1) · Daniela Lobo, MD, Ph.D. (1) · David Hodgins, PhD (1) · Donald Black, MD (1) · Greg Purvis, MSc (1) · Jon E Grant, JD, MD, MPH (1) · Jon Grant, MD (1) · Marc N Potenza, M.D., Ph.D. (1) · Marc N Potenza, MD, PhD (1) · Marc N. Potenza, M.D, Ph.D. (1) · Marc Potenza, MD (1)
PMID 36130734, PMID 20721537, PMID 22188239, PMID 23586456, PMID 23953269, PMID 24345329, PMID 25166480, PMID 36919514, PMID 38478366
1RC1DA028279-01 (1), 2017 (1), 2025 (1), K23DA000482 (1), K23MH069754 (1), R21MH067026 (1)